Maze Therapeutics, Inc. (MAZE) — 8-K Filings
All 8-K filings from Maze Therapeutics, Inc.. Browse 4 Current Event Report reports with AI-powered summaries and risk analysis.
8-K Filings (4)
-
Maze Therapeutics Files 8-K on Operations, Officer Changes
— Mar 25, 2026
Maze Therapeutics, Inc. filed an 8-K on March 25, 2026, reporting on its results of operations and financial condition (Item 2.02), changes in directors or offi -
Maze Therapeutics Announces Board and Executive Changes
— Oct 6, 2025 Risk: medium
On October 6, 2025, Maze Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates a d -
Maze Therapeutics Files 8-K: Material Agreement, Equity Sales
— Sep 11, 2025 Risk: medium
On September 10, 2025, Maze Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securitie -
Maze Therapeutics Announces Board and Compensation Changes
— Sep 2, 2025 Risk: medium
Maze Therapeutics, Inc. announced on September 2, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company rep
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX